List view / Grid view
11 December 2016 | By Drug Target Review
Included in this issue: Profiling proteins produced by cells to provide information about cell signalling pathways; HTS assays for the identification of small-molecule inhibitors of deubiquitinating enzymes; Preventing the spread of infectious diseases in transport hubs...
The advent of next-generation sequencing (NGS) techniques has revolutionised transcriptomics research and opened numerous avenues for scientific and clinical applications. While reverse transcriptase quantitative real-time polymerase chain reaction (RT-qPCR) is still considered the gold standard of gene expression analysis, its high throughput, single-nucleotide resolution and ever-plummeting costs have made NGS…
5 December 2016 | By Professor Jackie Hunter, BenevolentBio
Artificial Intelligence and machine learning present the industry with a real opportunity to do R&D differently, writes BenevolentBio's Jackie Hunter...
Next-generation sequencing (NGS) technologies hold great promise for unravelling the mysteries of biological systems, with the advent of DNA sequencing methods having greatly accelerated biomedical research, gaining broad applicability in disease diagnosis and therapeutics in recent years...
The covalent modification of proteins by the attachment of ubiquitin (ubiquitination) is best known for its function to label proteins for proteasomal degradation. However, ubiquitination also plays non-proteasomal roles during signal transduction, DNA repair and protein sorting...
23 November 2016 | By Rahul Kapur, Head of Medical Affairs, Novo Nordisk UK and Ireland
We caught up with Novo Nordisk’s Rahul Kapur, to find out what it’s like to be at the forefront of diabetes research and what it takes to get there...
17 November 2016 | By Niamh Louise Marriott, Digital Content Producer
D is for Diabetes - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest news and research into Diabetes...
16 November 2016 | By Niamh Louise Marriott, Digital Content Producer
C is for CRISPR - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest news and research of CRISPR technology
15 November 2016 | By Niamh Louise Marriott, Digital Content Producer
B is for Biomarkers - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest news and research on the subject of biomarkers.
14 November 2016 | By Niamh Louise Marriott, Digital Content Producer
A is for Alzheimer's - the first instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest news and research on the fight against this deadly disease
9 November 2016 | By Dr Hervé Perron, co-founder and Chief Scientific Officer of GeNeuro
GeNeuro's co-founder and CSO Dr Hervé Perron discusses how a HERV protein could be a target for a novel approach in treating multiple sclerosis...
3 November 2016 | By Niamh Louise Marriott, Digital Content Producer
The ethics of three parent babies has been widely debated - should it be used to save children from deadly mitochondrial diseases or are scientists "playing God"? Here's everything you need to know to decide...
27 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Researchers at UCLA discuss the growing trend of nanoscience, making their scientific predictions for the future of this tech and its global impact...
20 October 2016 | By Aaron Yao, PhD, University of Virginia School of Medicine
PhD student Aaron Yao highlights the shocking disparities between rural and urban eastern America and how the odds of cancer survival do not favour the impoverished...
10 October 2016 | By J.T. Kaminski, Director of Technology Services EMEA at IDBS
Drug Target Review brought you all the latest research and development live from the conference. Now read IDBS' J.T. Kaminski's round up of the event...
